The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Several guidelines and recommendations on the management of chronic myeloid leukemia
(CML) have been prepared by several scientific societies. The European LeukemiaNet …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed
the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-
TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to≥ 1 …